Regarding pharmaceutical patents, there are many aspects of the law that could be changed. We've heard a fair bit already about the details of the notice of compliance system, that is, the patent linkage system. I think patent term extension is a good idea. I acknowledge there is uncertainty in this, but I would be in favour of it.
The linkage system, the notice of compliance system, probably is due for review. We could look at it and pick out things that don't make sense, but it is necessary to look at the system as a whole. There are a bunch of compromises in that system. It's not a matter of saying that the innovator companies are very upset about not having a right of appeal. It seems unfair, but they do get other advantages. Without getting into details, I would say we could make some improvements by an overall review of the system.
I mentioned some of these details of doctrine that I'm hoping the courts will straighten out. They might be addressed. I would echo Ms. Garland's comments that there are a number of technical doctrines, such as the double patenting doctrine, loss of patent rights, and failure to pay fees on time, that could be addressed relatively easily, and I hope in an uncontroversial way.